TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9370179

Group type: EXPERIMENTAL
Intervention: Nonisotopic (cold) iothalamate measured by capillary electrophoresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clearance using 125I‐iothalamate
Number of subjects: 0
Study: 8421475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 2877131

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone substitution therapy (TTS)
Number of subjects: 7
Study: 29178769

Group type: EXPERIMENTAL
Intervention: Desensitizing agents (five commercially available agents applied according to manufacturers' instructions)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Desensitizing agents (five commercially available agents)
Number of subjects: 64
Study: 26331280

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention using the Achievable Benchmark of Care (ABC) method
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 2199
Study: 25100892

Group type: EXPERIMENTAL
Intervention: Caffeine (1.5 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Maltodextrin (CHO) (1 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Caffeine + Maltodextrin
Number of subjects: 8
Study: 22888676

Group type: EXPERIMENTAL
Intervention: Probiotic cheese comprising L. plantarum TENSIA (DSM 21380) consumed for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic cheese comprising L. plantarum TENSIA (DSM 21380)
Number of subjects: 0
Study: 19250082

Group type: EXPERIMENTAL
Intervention: Patients with ICD
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Max TVAR
Number of subjects: 57

Group type: COMPARATOR
Intervention: Patients without ICD
Number of subjects: 57
Study: 17584513

Group type: EXPERIMENTAL
Intervention: GH-2000 formula (discriminant function involving IGF-I and P-III-P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kreischa formula (discriminant function involving IGF-I, P-III-P, and IGFBP-3)
Number of subjects: 0
Study: 15211018

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistive training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (comparisons)
Number of subjects: 55
Study: 12398172

Group type: EXPERIMENTAL
Intervention: Thermaseal Plus sealer with ED Primer (Group A)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Thermaseal Plus sealer without ED Primer (Group B)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Panavia F with ED Primer (Group C)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Panavia F without ED Primer (Group D)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Negative control (entire root coated with wax)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Positive control (obturated with only a fitted master cone)
Number of subjects: 86
Study: 10534516

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy, 3 x 10(6) U s.c., three times a week (post-HD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 8869017

Group type: EXPERIMENTAL
Intervention: c7E3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2270581

Group type: EXPERIMENTAL
Intervention: 250 mg OTC three times/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7448347

Group type: EXPERIMENTAL
Intervention: Tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsules
Number of subjects: 0
Study: 31465810

Group type: EXPERIMENTAL
Intervention: Nutri-Score label applied to snacks
Number of subjects: 95
Study: 28249614

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with sufentanil
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sufentanil alone (control group)
Number of subjects: 97
Study: 27765058

Group type: EXPERIMENTAL
Intervention: Individualized sensorimotor exercise program (12 weeks: 3 weeks supervised centre-based and 9 weeks home-based)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 0
Study: 22582349

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22275471

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 19883809

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 40
Study: 17518959

Group type: EXPERIMENTAL
Intervention: Isotonic tongue press exercise
Number of subjects: 53

Group type: COMPARATOR
Intervention: Isometric tongue press exercise
Number of subjects: 53

Group type: COMPARATOR
Intervention: Isotonic head lift exercise
Number of subjects: 53
Study: 15470307

Group type: EXPERIMENTAL
Intervention: Long rest interval (160 s rest period)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Short rest interval (40 s rest period)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 15
Study: 11477461

Group type: EXPERIMENTAL
Intervention: High group (500 g/day fruit and vegetables and 200 ml/day fruit juice)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low group (100 g/day fruit and vegetables)
Number of subjects: 48
Study: 9700713

Group type: EXPERIMENTAL
Intervention: Atenolol treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 42
Study: 8206395

Group type: EXPERIMENTAL
Intervention: Octreotide (single injection)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms/day subcutaneously for three weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Octreotide (100 micrograms/day subcutaneously)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Octreotide in irritable bowel syndrome patients
Number of subjects: 11
Study: 2913770

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13
Study: 4601984

Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, CCNU
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DTIC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DTIC and BCNU
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intralesional BCG
Number of subjects: 80
Study: 31563344

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam (3 g intravenously every 8 h for 8-14 days)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Meropenem (1 g intravenously every 8 h for 8-14 days)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam
Number of subjects: 726

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 726
Study: 29018022

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 16791

Group type: COMPARATOR
Intervention: Obesity in men
Number of subjects: 16791

Group type: COMPARATOR
Intervention: Obesity in women
Number of subjects: 16791
Study: 26307616

Group type: EXPERIMENTAL
Intervention: Interactive web-based Pulmonary Rehabilitation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Pulmonary Rehabilitation programme
Number of subjects: 0
Study: 23660721

Group type: COMPARATOR
Intervention: Control group without additional training (group 1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mass training group with one supervised training session (150 min) after 2.5 months (group 2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Distributed training group with five monthly unsupervised training sessions of 30 min on a box trainer (group 3)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Distributed training group with five monthly unsupervised training sessions of 30 min on the LapMentor(®) (group 4)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Porcine Nissen model
Number of subjects: 39
Study: 22057609

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus photodynamic therapy (Sc/Rp + PDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing only (Sc/Rp)
Number of subjects: 20
Study: 18845008

Group type: EXPERIMENTAL
Intervention: Fluoxetine + Cognitive Behavioral Therapy (CBT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy (CBT)
Number of subjects: 93
Study: 16671972

Group type: EXPERIMENTAL
Intervention: Brief intervention using the 'Drink‐Less' protocol
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard advice (control condition)
Number of subjects: 127
Study: 15293581

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous morphine and procedural information
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 30 mg intravenous ketorolac and procedural information
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous morphine plus procedural and sensory information
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 30 mg intravenous ketorolac plus procedural and sensory information
Number of subjects: 74

Group type: COMPARATOR
Intervention: All interventions (morphine and ketorolac)
Number of subjects: 74
Study: 11743502

Group type: EXPERIMENTAL
Intervention: Chronic transfusion
Number of subjects: 130

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 130
Study: 9417009

Group type: EXPERIMENTAL
Intervention: Ring block
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Topical EMLA
Number of subjects: 52

Group type: COMPARATOR
Intervention: Topical placebo (no anesthetic)
Number of subjects: 52
Study: 7619991

Group type: COMPARATOR
Intervention: Control group (group A) - no additional interventions
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral administration of fluconazole (group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Single-dose intravenous administration of amphotericin B (group C)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intermittent bladder irrigation with amphotericin B at low concentration (group D)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intermittent bladder irrigation with amphotericin B at medium concentration (group E)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intermittent bladder irrigation with amphotericin B at high concentration (group F)
Number of subjects: 180
Study: 2571625

Group type: EXPERIMENTAL
Intervention: Trauma desensitization, hypnotherapy, and psychodynamic therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 112
Study: 346292

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Aspirin or Placebo
Number of subjects: 13
Study: 30608623

Group type: EXPERIMENTAL
Intervention: LARC FIRST video contraceptive counseling along with routine prenatal care
Number of subjects: 67

Group type: COMPARATOR
Intervention: Routine prenatal care alone
Number of subjects: 67
Study: 28646812

Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation (300 mg/d for weeks 1-4, 150 mg/d for weeks 5-8)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (rice flour placebo, similar dosing to intervention group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation
Number of subjects: 26
Study: 27099132

Group type: EXPERIMENTAL
Intervention: Alendronate (SIDIAP)
Number of subjects: 35537

Group type: EXPERIMENTAL
Intervention: Alendronate (DHR)
Number of subjects: 35537
Study: 23358230

Group type: EXPERIMENTAL
Intervention: e-Cigarette
Number of subjects: 14
Study: 20888728

Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention program (n=208)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual care (medical assessment) (n=106)
Number of subjects: 314
Study: 19960132

Group type: EXPERIMENTAL
Intervention: Peer support (n=45)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care (n=50)
Number of subjects: 95
Study: 17118704

Group type: EXPERIMENTAL
Intervention: Warm-up only
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Stretching only
Number of subjects: 14

Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Warm-up and stretching
Number of subjects: 14
Study: 14697682

Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles
Number of subjects: 156

Group type: COMPARATOR
Intervention: Neutrally wedged insoles (Control)
Number of subjects: 156
Study: 11303598

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine/oltipraz (NAC/OLZ) combination, OLZ 200 mg (Arm B)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine/oltipraz (NAC/OLZ) combination, OLZ 400 mg (Arm C)
Number of subjects: 19

Group type: COMPARATOR
Intervention: N-acetylcysteine/oltipraz (NAC/OLZ) combination, placebo (Arm A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine/oltipraz (NAC/OLZ) combination
Number of subjects: 19
Study: 8884875

Group type: EXPERIMENTAL
Intervention: Clodronate (800 mg orally four times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (280 mg orally twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate with clodronate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clodronate with estramustine phosphate
Number of subjects: 12
Study: 1669598

Group type: EXPERIMENTAL
Intervention: Local immunotherapy (LI) by inhalation of a powder extract of house dust mite (HDM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Parenteral immunotherapy (PI) by injection
Number of subjects: 10
Study: 6601670

Group type: EXPERIMENTAL
Intervention: SRW intranasal immunotherapy (n = 11); cumulative AgE doses from 3 to 59 micrograms (mean 21)
Number of subjects: 20

Group type: COMPARATOR
Intervention: OG control (n = 9)
Number of subjects: 20
Study: 30840130

Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban therapy (Group 1, n=32)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Interrupted apixaban therapy (Group 2, n=65)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 97
Study: 29235300

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine and Western medicine treatment (Buxin Yishen decoction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Western medicine treatment (control group)
Number of subjects: 0
Study: 27647057

Group type: EXPERIMENTAL
Intervention: Multisession telephone counseling from study staff (n=804)
Number of subjects: 1618

Group type: COMPARATOR
Intervention: Referral to the state quitline for proactive outreach and counseling (n=814)
Number of subjects: 1618
Study: 24435207

Group type: EXPERIMENTAL
Intervention: Silodosin (8 mg/day for 6 months)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (no silodosin)
Number of subjects: 105
Study: 23057616

Group type: EXPERIMENTAL
Intervention: Informational intervention (educational video and handbook)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informational intervention plus financial assistance program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual dialysis care
Number of subjects: 0
Study: 19079954

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment combined with cognitive-behavioral therapy (CBT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Waiting list control group (3 months)
Number of subjects: 130
Study: 17846890

Group type: EXPERIMENTAL
Intervention: Group HIV prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control, career exploration condition
Number of subjects: 0
Study: 15357013

Group type: EXPERIMENTAL
Intervention: Würzburg training program of phonological awareness
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular kindergarten program (Control)
Number of subjects: 80
Study: 11719017

Group type: EXPERIMENTAL
Intervention: Eudragit L 30 D‐55 coated capsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eudragit FS 30 D coated capsules
Number of subjects: 0
Study: 9620358

Group type: EXPERIMENTAL
Intervention: Anti-CD3 monoclonal antibody (mAb) OKT3 and phorbol myristate acetate (PMA) stimulation in young humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-CD3 monoclonal antibody (mAb) OKT3 and phorbol myristate acetate (PMA) stimulation in elderly humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-CD3/PMA stimulation in elderly humans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting T cells from young humans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting T cells from elderly humans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting and stimulated T cells
Number of subjects: 0
Study: 7616847

Group type: EXPERIMENTAL
Intervention: High-dose intravenous Intralipid infusion (test 1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heparin (30 U/min) plus low-dose Intralipid infusion (test 2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control study (test 3)
Number of subjects: 6
Study: 1969013

Group type: EXPERIMENTAL
Intervention: Heparin infusion
Number of subjects: 97

Group type: COMPARATOR
Intervention: Heparin bolus
Number of subjects: 97

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 97
Study: 6448885

Group type: EXPERIMENTAL
Intervention: L-Deprenil plus L-5-HTP and benzerazide
Number of subjects: 18

Group type: COMPARATOR
Intervention: L-5-HTP and benzerazide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30810061

Group type: EXPERIMENTAL
Intervention: Exercise training (EXT) - 3 × 45 min of supervised exercise per week at 60‐85% heart rate reserve for 12 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise training (EXT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON) - routine care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study: 29081098

Group type: EXPERIMENTAL
Intervention: Alanyl glutamine injection plus conventional therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 80
Study: 26480877

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 2 g by topical application
Number of subjects: 111

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 111
Study: 23596780

Group type: EXPERIMENTAL
Intervention: Xiaochaihu Decoction (XD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Shenyan Kangfu Tablet (SKT)
Number of subjects: 70
Study: 21321793

Group type: EXPERIMENTAL
Intervention: Filipino Americans
Number of subjects: 20712

Group type: EXPERIMENTAL
Intervention: Korean Americans
Number of subjects: 20712

Group type: EXPERIMENTAL
Intervention: Japanese Americans
Number of subjects: 20712

Group type: COMPARATOR
Intervention: Non-Hispanic whites
Number of subjects: 20712
Study: 19180358

Group type: EXPERIMENTAL
Intervention: Trehalose
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trehalose/Fructose combination
Number of subjects: 21

Group type: COMPARATOR
Intervention: Glucose control
Number of subjects: 21
Study: 17192336

Group type: EXPERIMENTAL
Intervention: C-peptide 1.5 mg/day (divided into four subcutaneous doses) for 6 months
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: C-peptide 4.5 mg/day for 6 months
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: C-peptide treatment
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 15232043

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 28
Study: 11578284

Group type: EXPERIMENTAL
Intervention: Hernioplasty (polypropylene mesh or plug)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Herniorrhaphy (primary suture)
Number of subjects: 200
Study: 9462481

Group type: EXPERIMENTAL
Intervention: Passive listening
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Simple reaction task
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Choice-reaction task (target probability = 0.5)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Early auditory gamma band responses
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Late gamma responses
Number of subjects: 9
Study: 7945477

Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg/kg/day)
Number of subjects: 122
Study: 3115044

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meperidine 0.5 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 8
Study: 29723220

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction in SLE patients with lower education (9 years) compared to normal cognitive function (12 years), P = 0.006
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction in SLE patients with higher body mass index (26.7) compared to normal cognitive function (24.3), P = 0.03
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction in SLE patients with positive IgG anticardiolipin antibodies (50%) compared to normal cognitive function (18%), P = 0.009
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction in SLE patients with a higher median number of concomitant NPSLE syndromes (3) compared to normal cognitive function (1), P = 0.04
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CCL2 levels in CSF of SLE patients with cognitive dysfunction [886.1 (374.9–1439.7) pg/mL] compared to normal cognitive function [515.8 (3.2–1958.2) pg/mL], P = 0.04
Number of subjects: 100
Study: 28870217

Group type: EXPERIMENTAL
Intervention: MPA (10 mg) administered daily from early follicular phase
Number of subjects: 204

Group type: COMPARATOR
Intervention: Natural cycle IVF
Number of subjects: 204
Study: 26216383

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg i.v. q4 weeks during the first three cycles of carboplatin (AUC5) plus doxorubicin (PLD 30 mg/m2 or doxorubicin 50 mg/m2 i.v., day 1, q4 weeks, for six cycles)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg i.v. q4 weeks
Number of subjects: 23
Study: 22218118

Group type: EXPERIMENTAL
Intervention: Losartan, 25 mg, twice per day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Losartan + N-acetyl cysteine (NAC), 600 mg twice daily
Number of subjects: 70